Literature DB >> 19383329

Mutant p53 targeting by the low molecular weight compound STIMA-1.

Nicole Zache1, Jeremy M R Lambert, Nina Rökaeus, Jinfeng Shen, Pierre Hainaut, Jan Bergman, Klas G Wiman, Vladimir J N Bykov.   

Abstract

Reactivation of mutant p53 in human tumor cells should induce cell death by apoptosis and thus eliminate the tumor. Several small molecules that reactivate mutant p53 have been identified. Here we show that STIMA-1, a low molecular weight compound with some structural similarities to the previously identified molecule CP-31398, can stimulate mutant p53 DNA binding in vitro and induce expression of p53 target proteins and trigger apoptosis in mutant p53-expressing human tumor cells. Human diploid fibroblasts are significantly more resistant to STIMA-1 than mutant or wild type p53-carrying tumor cells. STIMA-1 may provide new insights into possible mechanisms of mutant p53 reactivation and thus facilitate the development of novel anticancer drugs that target mutant p53-carrying tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19383329      PMCID: PMC5527782          DOI: 10.1016/j.molonc.2008.02.004

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  35 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

Review 2.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

Review 3.  Clinical implications of p53 mutations in lung cancer.

Authors:  Barbara G Campling; Wafik S el-Deiry
Journal:  Methods Mol Med       Date:  2003

4.  Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Authors:  Vladimir J N Bykov; Natalia Issaeva; Nicole Zache; Alexandre Shilov; Monica Hultcrantz; Jan Bergman; Galina Selivanova; Klas G Wiman
Journal:  J Biol Chem       Date:  2005-07-01       Impact factor: 5.157

5.  The IARC TP53 database: new online mutation analysis and recommendations to users.

Authors:  Magali Olivier; Ros Eeles; Monica Hollstein; Mohammed A Khan; Curtis C Harris; Pierre Hainaut
Journal:  Hum Mutat       Date:  2002-06       Impact factor: 4.878

6.  PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.

Authors:  Vladimir J N Bykov; Nicole Zache; Helene Stridh; Jacob Westman; Jan Bergman; Galina Selivanova; Klas G Wiman
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

7.  Characterization of the p53-rescue drug CP-31398 in vitro and in living cells.

Authors:  Thomas M Rippin; Vladimir J N Bykov; Stefan M V Freund; Galina Selivanova; Klas G Wiman; Alan R Fersht
Journal:  Oncogene       Date:  2002-03-28       Impact factor: 9.867

8.  Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

Authors:  Vladimir J N Bykov; Natalia Issaeva; Alexandre Shilov; Monica Hultcrantz; Elena Pugacheva; Peter Chumakov; Jan Bergman; Klas G Wiman; Galina Selivanova
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

Review 9.  Small molecules that reactivate mutant p53.

Authors:  V J N Bykov; G Selivanova; K G Wiman
Journal:  Eur J Cancer       Date:  2003-09       Impact factor: 9.162

10.  Role of cysteine residues in regulation of p53 function.

Authors:  R Rainwater; D Parks; M E Anderson; P Tegtmeyer; K Mann
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

View more
  35 in total

1.  Determination and stability of CP-31398 in plasma from experimental animals by LC-MS/MS.

Authors:  Miguel Muzzio; Zhihua Huang; William D Johnson; David L McCormick; Izet M Kapetanovic
Journal:  J Pharm Biomed Anal       Date:  2011-07-22       Impact factor: 3.935

Review 2.  Targeting the p53 pathway.

Authors:  Vita M Golubovskaya; William G Cance
Journal:  Surg Oncol Clin N Am       Date:  2013-07-30       Impact factor: 3.495

Review 3.  Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.

Authors:  Kanaga Sabapathy; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2017-09-26       Impact factor: 66.675

Review 4.  Translational approaches targeting the p53 pathway for anti-cancer therapy.

Authors:  Frank Essmann; Klaus Schulze-Osthoff
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

Review 5.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

Review 6.  Pharmacological activation of p53 in cancer cells.

Authors:  Mohammad Athar; Craig A Elmets; Levy Kopelovich
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  CP-31398 inhibits the growth of p53-mutated liver cancer cells in vitro and in vivo.

Authors:  Xing-Xing He; Yu-Nan Zhang; Jun-Wei Yan; Jing-Jun Yan; Qian Wu; Yu-Hu Song
Journal:  Tumour Biol       Date:  2015-08-07

8.  Mutant p53 targeting by the low molecular weight compound STIMA-1.

Authors:  Nicole Zache; Jeremy M R Lambert; Nina Rökaeus; Jinfeng Shen; Pierre Hainaut; Jan Bergman; Klas G Wiman; Vladimir J N Bykov
Journal:  Mol Oncol       Date:  2008-03-07       Impact factor: 6.603

Review 9.  Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.

Authors:  Bryant England; Tiangui Huang; Michael Karsy
Journal:  Tumour Biol       Date:  2013-06-05

Review 10.  Targeting mutant p53 for efficient cancer therapy.

Authors:  Vladimir J N Bykov; Sofi E Eriksson; Julie Bianchi; Klas G Wiman
Journal:  Nat Rev Cancer       Date:  2017-12-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.